11-05 :: May/June 2011
nanotimes
Companies Facts
AMRI also will receive royalties on worldwide sales of any commercialized compounds.
http://www.amriglobal.com/
ting of patents for an application system, which for the first time allows long-term and outpatient admi- nistration of therapeutic substances into brain tissue using the so-called Convection Enhanced Delivery (CED).
A B
http://www.antisense-pharma.com
erkeley Design Automation Inc., provider of the Analog FastSPICE™ unified circuit verification
platform announced that Mohagi, a developer of energy-efficient analog and mixed-signal IP, has se- lected the company‘s Analog FastSPICE Nano SPICE simulator (AFS Nano) for analog and mixed-signal IP verification. Priced at $1,900 for a 1-year time- based license, AFS Nano is up to 10x faster than traditional SPICE, is foundry certified down to 28nm, and supports up to 5,000 element circuits.
Berkeley Design Automation, Inc. (BDA) is the reco- gnized leader in advanced analog, mixed-signal, and RF (AMS/RF) verification. The BDA Analog FastSPICE unified circuit verification platform (AFS Platform) combines the accuracy, performance, and capacity needed to verify GHz designs in nanometer-scale silicon.
http://www.berkeley-da.com B
io-Gate AG (ISIN: DE000BGAG999), a German provider of antimicrobial products and multifunc-
ntisense Pharma GmbH, a biopharmaceutical company in Germany, has announced the gran-
tional surfaces for medical applications, announced the resignation of Dr Michael Wagener from his position on the Board of Management for personal reasons. His duties will be restructured at executive level.
Furthermore, the company published the results for 2010. Sales increased by 50% to EUR3,099,000. The loss clearly decreaed to EUR1,622,000 (2009: EUR2,614,000). As of balance sheet day (31.12.) the equity ratio increased to 70% from 62% in 2009.
http://www.bio-gate.de
B
iotage (STO: BIOT), a leading supplier of tools and technology for analytical and medicinal
chemistry, announced a collaborative research ag- reement with The Laboratory of Peptide & Protein Chemistry & Biology (PeptLab) located in Florence, Italy. The renowned peptide research facility, led by Professor Anna Maria Papini, has agreed to contri- bute technical input towards the future development of Biotage related products as well as provide trai- ning facilities for demonstrating Biotage’s range of peptide synthesis, purification and resin products.
PeptLab is an interdepartmental structure of the University of Florence, located at the Polo Scientifico e Tecnologico in Sesto Fiorentino, founded in 2004 by Professor Paolo Rovero (Dept. of Pharmaceutical Sciences), Professor Anna Maria Papini and Dr. Ma- rio Chelli (Dept. of Organic Chemistry ‘Ugo Schiff’), and Professor Francesco Lolli (Dept. of Neurological Sciences).
http://www.biotage.com
http://www.unifi.it/peptlab/PeptLab/index_en.html
19
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95